Literature DB >> 23528904

Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.

Michael W Bishop1, Hong Yin, Hiroyuki Shimada, Alexander J Towbin, Alexander Miethke, Brian Weiss.   

Abstract

MYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23528904     DOI： 10.1097/MPH.0b013e3182847376

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Differential diagnosis and management of liver tumors in infants.

Authors:  Israel Fernandez-Pineda; Rosa Cabello-Laureano
Journal:  World J Hepatol       Date:  2014-07-27

2.  Diagnostic implications of intrapatient genetic tumor heterogeneity.

Authors:  Ana P Berbegall; Samuel Navarro; Rosa Noguera
Journal:  Mol Cell Oncol       Date:  2015-09-11

3.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Authors:  A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

Review 4.  A review of neuroblastoma image-defined risk factors on magnetic resonance imaging.

Authors:  Alan M Chen; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04

5.  Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology.

Authors:  Lily Tran; Carrie Fitzpatrick; Susan L Cohn; Peter Pytel
Journal:  Virchows Arch       Date:  2017-09-01       Impact factor: 4.064

6.  Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Authors:  Ana P Berbegall; Dominik Bogen; Ulrike Pötschger; Klaus Beiske; Nick Bown; Valérie Combaret; Raffaella Defferrari; Marta Jeison; Katia Mazzocco; Luigi Varesio; Ales Vicha; Shifra Ash; Victoria Castel; Carole Coze; Ruth Ladenstein; Cormac Owens; Vassilios Papadakis; Ellen Ruud; Gabriele Amann; Angela R Sementa; Samuel Navarro; Peter F Ambros; Rosa Noguera; Inge M Ambros
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.